Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2005-02-23
2009-10-06
Mondesi, Robert B (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S023000, C435S069100
Reexamination Certificate
active
07598027
ABSTRACT:
Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.
REFERENCES:
patent: 5750365 (1998-05-01), Chiu et al.
patent: 5925528 (1999-07-01), Chiu
patent: 6913877 (2005-07-01), Chaplen et al.
patent: 7183066 (2007-02-01), Fernandez-Salas et al.
patent: 7208285 (2007-04-01), Steward et al.
patent: 7264946 (2007-09-01), Bogin et al.
patent: 2003/0219462 (2003-11-01), Steward et al.
patent: 2004/0013687 (2004-01-01), Simpson et al.
patent: 2004/0014024 (2004-01-01), Yayon et al.
patent: 2004/0058348 (2004-03-01), Bogin et al.
patent: 2004/0072270 (2004-04-01), Fernandez-Salas et al.
patent: 2004/0204388 (2004-10-01), Lynch et al.
patent: 2005/0123567 (2005-06-01), First
patent: 2005/0129677 (2005-06-01), Li et al.
patent: 2005/0148511 (2005-07-01), Bogin et al.
patent: 2006/0078900 (2006-04-01), Mendrick et al.
patent: 2006/0127914 (2006-06-01), Yon et al.
patent: 2007/0118934 (2007-05-01), Yu et al.
patent: 2007/0135514 (2007-06-01), Lynch et al.
patent: 2008/0064054 (2008-03-01), Fernandez-Salas et al.
patent: 2008/0160561 (2008-07-01), Fernandez-Salas et al.
patent: 2008/0182799 (2008-07-01), Fernandez-Salas et al.
patent: WO 02/102854 (2002-12-01), None
patent: WO 02/102972 (2002-12-01), None
patent: WO 02/102973 (2002-12-01), None
patent: WO 2004/110487 (2004-12-01), None
Keller, James E. et al, FEBS Letters, vol. 456, 1999, pp. 137-142, Persistence of botulinum neurotoxin action in cultured spinal cord cells.
Dong, min et al, Science, vol. 312, Apr. 28, 2006, pp. 592-596, SV2 is the protein receptor for Botulinum neurotoxin A.
Keller et al, 1999, reference of record.
Aoki, KR, Future Aspects of Botulinum neurotoxins, Journal of Neural Transmission, vol. 115(4), Apr. 2008, pp. 567-573.
Maksymowych, A.B e tal, Binding and Trnascytosis of Botulinum Nuerotoxin by Polarized Human colon carcinoma cells, The Journal of Biological Chemistry, vol. 273(34), Aug. 21, 1998, pp. 21950-21957.
Stecher, B et al, Federation of European Biochemical Societies, vol. 248(1-2), pp. 23-27, May 1989, Reduction chain separation of botulinum A toxin-a prerequisite to its inhibitory action on exocytosis in chromaffin cells.
Daniels-Holgate, P.U. et al, Journal of Neuroscience Research, vol. 44, pp. 263-271, 1996, Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by Its heavy chain.
Lalli, Giovanna et al, Journal of Cell Science, vol. 112, pp. 2715-2724, 1999, Functional characterization of tetanus and botulinum neurotoxins binding domains.
Lacy, D. Borden et al, Nature Structural Biology, vol. 5(10), Oct. 1998, Crystal structure of botulinum neurotoxin type A and implications for toxicity.
Schiavo, Giampietro et al, Physiol. Rev., vol. 80, pp. 717-766, 2000.
Onose, Hiroyuki et al, European Journal of Endocrinology, 1999, vol. 140, pp. 169-173, Overexpression of fibroblast growth factor receptor 3 in a human thyroid carcinoma cell line results in overgrowth of the confluent cultures.
Nemoz-Gaillard, Eric et al, Expression of SNARE proteins in neteroendocrine cell lines and functional role of tetanus toxin- sensitive protein in cholecystokinin release.
L-M. Sturla et al., FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells, 89(7) Br. J. Cancer 1276-1284 (2003).
M. Kanai et al., Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein, 272(10) J. Biol. Chem 6621-6628 (1997).
Janet E. Henderson et al., Expression of FGFR3 with the G380R achondroplasia mutation inhibits proliferation and maturation of CFK2 chondrocytic cells, 15(1) J. Bone Miner. Res. 155-165 (2000).
Noriko Yokosawa et al., Binding ofClostridium botulinumtype C neurotoxin to different neuroblastoma cell lines, 57(1) Infect. Immun. 272-277 (1989).
Noriko Yokosawa et al., Binding of botulinum type Cl, D and E neurotoxins to neuronal cell lines and synaptosomes, 29(2) Toxicon 261-264 (1991).
Tei-ichi Nishiki et al., Identification of protein receptor forClostridium botulinumtype B neurotoxin in rat brain synaptosomes, 269(14) J. Biol. Chem. 10498-10503 (1994).
Hiroyuki Onose et al., Over-expression of fibroblast growth factor receptor 3 in a human thyroid carcinoma cell line results in overgrowth of the confluent cultures, 140(2) Eur. J. Endocrinol. 169-173 (1999).
Elizabeth E. Plowright et al., Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis, 95(3) Blood 992-998 (2000).
Yukako Fujinaga et al., Molecular characterization of binding subcomponents ofClostridium botulinumtype C progenitor toxin for intestinal epithelial cells and erythrocytes, 150(Pt 5) Microbiology 1529-1538 (2004).
Atsushi Nishikawa et al., The receptor and transporter for internalization ofClostridium botulinumtype C progenitor toxin into HT-29 cells, 319(2) Biochem. Biophys. Res. Commun. 327-333 (2004).
Erik A. Mijan and Eric G. Bremer, Regulation of Growth Factor Receptors by Gangliosides, 2002(160)Sci. STKE.RE15(2002).
Akio Shimizu et al, A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells, 276(14) J. Biol. Chem. 11031-11040 (2001).
C. J. Powers et al., Fibroblast growth factors, their receptors and signaling 7(3)Endocr. Relat. Cancer. 165-197 (2000).
Bernhard Reuss & Oliver von Bohlen und Halbach, Fibroblast growth factors and their receptors in the central nervous system, 313(2) Cell Tissue Res. 139-157 (2003).
Aoki Kei Roger
Fernandez-Salas Ester
Garay Patton E.
Allergan Inc.
Condino Debra
German Joel B.
Mondesi Robert B
Portner Ginny
LandOfFree
Botulinum toxin screening assays does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Botulinum toxin screening assays, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Botulinum toxin screening assays will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4089992